Daniel Cahill
Affiliations: | Neurosurgery | M. D. Anderson Cancer Center, Houston, TX, United States |
Website:
http://faculty.mdanderson.org/Daniel_Cahill/Default.asp?SNID=998364111Google:
"Daniel Cahill"Mean distance: 16.49 (cluster 24) | S | N | B | C | P |
Cross-listing: Neuropathology Tree
Parents
Sign in to add mentor| Bert Vogelstein | grad student | 2001 | Johns Hopkins (Chemistry Tree) | |
| (Chromosomal instability in human cancer.) | ||||
| David N. Louis | post-doc | Harvard Medical School and Masssachusetts General Hospital | ||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Batool SM, Escobedo AK, Hsia T, et al. (2024) Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas. Nature Communications. 15: 7074 |
| Spitzer A, Gritsch S, Nomura M, et al. (2024) Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma. Cancer Cell |
| Tateishi K, Miyake Y, Nakamura T, et al. (2023) Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma. Acta Neuropathologica Communications. 11: 186 |
| Miller JJ, Gonzalez Castro LN, McBrayer S, et al. (2022) Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro-Oncology |
| Mathewson ND, Ashenberg O, Tirosh I, et al. (2021) Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell |
| Richardson LG, Nieman LT, Stemmer-Rachamimov AO, et al. (2020) IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. Oncoimmunology. 9: 1806662 |
| Park JW, Sahm F, Steffl B, et al. (2020) TERT and DNMT1 expression predict sensitivity to decitabine in gliomas. Neuro-Oncology |
| Neftel C, Laffy J, Filbin MG, et al. (2019) An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell |
| Tanaka S, Batchelor TT, Iafrate AJ, et al. (2019) PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma. Acta Neuropathologica Communications. 7: 66 |
| Juratli T, Jones P, Wang N, et al. (2019) Rare-04. Targeted Treatment Of Papillary Craniopharyngiomas Harboring Brafv600E Mutations Neuro-Oncology. 21 |